

Michael Putman MSci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2250412/publications.pdf>

Version: 2024-02-01

36
papers

836
citations

623188

14
h-index

500791

28
g-index

36
all docs

36
docs citations

36
times ranked

1401
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinicopathologic Associations in a Large International Cohort of Patients With Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2022, 74, 1013-1018.	1.5	4
2	Rapid Adoption of Telemedicine in Rheumatology Care During the COVID-19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees. <i>ACR Open Rheumatology</i> , 2022, 4, 128-133.	0.9	6
3	SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2022, 74, 766-775.	2.9	117
4	Dr. Conway et al reply. <i>Journal of Rheumatology</i> , 2022, 49, 120.2-121.	1.0	0
5	Where do we go after GACTA?. <i>Rheumatology</i> , 2022, , .	0.9	0
6	Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology. <i>Mayo Clinic Proceedings</i> , 2022, 97, 250-260.	1.4	10
7	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>Lancet Rheumatology</i> , The, 2022, 4, e237-e240.	2.2	30
8	The impact of COVID-19 on rheumatology training—results from the COVID-19 Global Rheumatology Alliance trainee survey. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkac001.	0.3	7
9	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. <i>Rheumatology</i> , 2022, 61, SI143-SI150.	0.9	40
10	Challenging wisely: how to move beyond 1Âmg/kg then taper™. <i>Rheumatology</i> , 2022, 62, 3-6.	0.9	1
11	There is no diagnosis of exclusion in rheumatology. <i>Rheumatology</i> , 2022, , .	0.9	3
12	Benchmarking tocilizumab use for giant cell arteritis. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.3	7
13	Any Given Monday: Association Between Desk Rejections and Weekend Manuscript Submissions to Rheumatology Journals. <i>Journal of Rheumatology</i> , 2022, 49, 652-653.	1.0	2
14	Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2021, 48, 1053-1059.	1.0	22
15	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2021, 73, 36-47.	2.9	52
16	Publication Trends in Rheumatology Systematic Reviews and Randomized Clinical Trials, 1995–2017. <i>Journal of Rheumatology</i> , 2021, 48, 305-306.	1.0	1
17	Further Investigation of Representation of Women as Authors of Rheumatology Articles From 2005 to 2020: Comment on the Article by Bagga et al. <i>Arthritis and Rheumatology</i> , 2021, 73, 546-547.	2.9	0
18	Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. <i>Lancet Rheumatology</i> , The, 2021, 3, e71-e82.	2.2	18

#	ARTICLE	IF	CITATIONS
19	Long-Term Care Resident Awareness and Interest in Spasticity Treatments. <i>Geriatrics (Switzerland)</i> , 2021, 6, 21.	0.6	0
20	The protective effect of rheumatic disease agents in COVID-19. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101659.	1.4	9
21	Authorship Trends in the Rheumatology Literature, 1990–2020. <i>Journal of Rheumatology</i> , 2021, 48, 1493-1494.	1.0	1
22	Extensive soft tissue xanthomatosis masquerading as tophaceous gout in a normolipidemic man. <i>Rheumatology</i> , 2021, 60, e381-e383.	0.9	0
23	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 1767-1768.	2.9	0
24	Industry Payments to Practicing US Rheumatologists, 2014–2019. <i>Arthritis and Rheumatology</i> , 2021, 73, 2138-2144.	2.9	22
25	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , 2021, 7, e001814.	1.8	121
26	Dr. Conway et al reply. <i>Journal of Rheumatology</i> , 2021, , jrheum.210913.	1.0	2
27	Trends in Published Clinical Trial Phases Among Surgical Specialties, 2007–2017. <i>Annals of Surgery</i> , 2021, 273, e178-e179.	2.1	2
28	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e855-e864.	2.2	38
29	A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. <i>Annals of Internal Medicine</i> , 2020, 172, 819-821.	2.0	177
30	Tracking clinical resources for coronavirus disease 2019. <i>Current Opinion in Rheumatology</i> , 2020, 32, 441-448.	2.0	3
31	Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1191-1201.	1.6	19
32	Publication Rate and Journal Review Time of COVID-19–Related Research. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2290-2291.	1.4	18
33	The Quality of Randomized Controlled Trials in High-impact Rheumatology Journals, 1998–2018. <i>Journal of Rheumatology</i> , 2020, 47, 1446-1449.	1.0	5
34	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 659-666.	1.3	57
35	<i><i>Festina lente</i></i> : hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 734-736.	0.5	35
36	Learning from Adversity: Lessons from the COVID-19 Crisis. <i>Journal of Rheumatology</i> , 2020, 47, 791-792.	1.0	7